Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Interest & Investment Income: 2017-2025

Historic Interest & Investment Income for UroGen Pharma (URGN) over the last 8 years, with Sep 2025 value amounting to $979,000.

  • UroGen Pharma's Interest & Investment Income fell 62.33% to $979,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $7.1 million, marking a year-over-year decrease of 4.26%. This contributed to the annual value of $8.7 million for FY2024, which is 149.27% up from last year.
  • Latest data reveals that UroGen Pharma reported Interest & Investment Income of $979,000 as of Q3 2025, which was down 24.63% from $1.3 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Interest & Investment Income ranged from a high of $2.8 million in Q4 2024 and a low of $2,000 during Q1 2022.
  • Its 3-year average for Interest & Investment Income is $1.5 million, with a median of $1.5 million in 2023.
  • In the last 5 years, UroGen Pharma's Interest & Investment Income slumped by 92.51% in 2021 and then surged by 31,400.00% in 2023.
  • UroGen Pharma's Interest & Investment Income (Quarterly) stood at $20,000 in 2021, then spiked by 1,930.00% to $406,000 in 2022, then soared by 278.82% to $1.5 million in 2023, then spiked by 78.80% to $2.8 million in 2024, then crashed by 62.33% to $979,000 in 2025.
  • Its Interest & Investment Income stands at $979,000 for Q3 2025, versus $1.3 million for Q2 2025 and $2.1 million for Q1 2025.